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CHAPTER I 
 
 
BACKGROUND AND REVIEW OF LITERATURE 
 
Since the mid 1980s, structure-based drug design has been greatly enhanced to 
guide the development of more effective compounds. Taking advantage of X-ray 
crystallography and computer modeling, the crystal structure of a receptor in complex 
with a drug candidate can be solved. The study of structure reveals active sites of 
receptors, such as the positions of the hydrogen bonding donors and acceptors in a 
receptor binding pocket as well as cavities in the binding site into which substituents 
might be placed in a drug candidate to increase its binding affinity for the receptor 
compounds.1 
In the field of molecular biology, a receptor is a protein that binds to a ligand and 
initiates a cellular response. The retinoic acid receptors (RARs) bind retinoids and 
mediate both organismal and cellular effects.2 The term “retinoid” includes both natural 
forms of vitamin A, which is a generic term for any compound possessing the biological 
activity of retinol, and the many synthetic analogs of retinol, such as arotinoids and 
heteroarotinoids, with or without biological activity.3 Vitamin A, found in foods from 
animal sources, exists in forms of retinol (alcohol) [1], retinal (aldehyde) [2] and retinoic 
acid (acid) [3, 5, 6] (see Figure 1-1). Provitamin A carotenoids, including α-carotene, β-
carotene and β-cryptoxanthin, found in foods from plant sources can be converted into
 2 
 retinol in the body. Among these carotenoids, β-carotene [4] (see Figure 1-1) is 
converted into retinol with the highest efficiency.4  
                            
                 1  All-trans retinol                                                                          2  11-cis-retinal                               
 
                 3  All-trans retinoic acid 
 
4  β-carotene 
 
                                                              
               5  9-cis retinoic acid                                                                       6  13-cis retinoic acid 
Figure 1-1. Naturally occurring forms of retinoids 
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The basic structure of natural retinoid molecules is composed of a cyclic end 
group, a polyene side chain and a polar end group5 (see Figure 1-1). The end groups and 
the conjugated system with alternating C=C double bonds in the polyene side chain 
create dramatic modification of retinoids.5 Both arotinoids [7, 8] (see Figure 1-2) and 
heteroarotinoids [9a, 9b, 10a, 10b] (see Figure 1-3) have at least one aromatic group in 
their basic structure, but the latter has a heteroatom in the cyclic ring.  
                                           
                7  Am 580                                                                              8  TARGRETIN, LGD 1069 
Figure 1-2. Examples of arotinoids 
 
              
                9a  X=O;   9b  X=S                                                                  10a  X=O;   10b  X=S 
Figure 1-3. Examples of heteroarotinoids 
 
The three retinoic acid receptor (RAR) and three retinoid X receptor (RXR) 
proteins (α, β and γ, and their isoforms), which specifically bind retinoids, belong to the 
nuclear receptor (NR) superfamily. The activity of those proteins is similar to the steroid 
hormone receptors which can enter the cell nucleus and modulate gene expression by 
interacting with specific DNA sequences upstream of the target genes in response to the 
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activation by the ligand.6 This regulation functions through a receptor conformational 
change, which is induced by binding of the ligand and later results in physiological 
changes that induce the biological activities of the ligands.7,8 RARs are activated by two 
common isomers of retinoic acid (RA), namely all trans-retinoic acid (T-RA [3]) and 9-
cis-retinoic acid (9C-RA [5]), but RXRs are activated only by 9C-RA [5]. When binding 
T-RA [3], an endogenous retinoid, the RARs become transcriptionally active. RXRs 
function as common partners to many other NRs, but the actual biological role of RXRs 
is still an enigma.9 
 
Nuclear receptors exhibit a modular structure consisting of six regions (A through 
F).10 The A-B region (N-terminal) shows ligand-independent transcriptional activation 
functionality (AF-1). Each of the three isotypes of RAR and RXR contains isoforms that 
differ only in their A-region. RARα and RARγ have two major isoforms (α1 and α2; γ1 
and γ2), but RARβ has four major isoforms (β1, β2, β3 and β4) and a truncated isoform 
(β’).11 There are two major isoforms in each of the RXR isotypes, i.e., RXRα (α1 and 
α2), RXRβ (β1 and β2) and RXRγ (γ1 and γ2)9. The DNA-binding domain (DBD; region 
C), which contains two zinc fingers, is highly conserved and binds specific DNA 
sequences12 called hormone response elements (HRE) but, in the case of the RARs, it is 
called the retinoic acid response element (RARE).13 The ligand-binding domain (LBD; 
region E), which is  highly conserved in both structure and sequence between the RAR 
and isotypes, contains a ligand-binding pocket (LBP) and a ligand-dependent activation 
function (AF-2)12 which suggests different responses for binding of ligands.13 The highly 
conserved regions of DBD and LBD in both receptors are indicated in Figure 1-4. RARs 
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and RXRs only share 29% homology in their LBD.14 The hinge domain (region D) 
connects the LBD to the DBD. The sequence of the undefined C-terminus (region F) 
varies among the different nuclear receptors.  
 
Nuclear receptors typically bind to their target sequences as dimers.3 In addition 
to ligand binding, the ligand-binding domain of nuclear receptors participates in the 
activity of homo- and/or heterodimerization. The LBD of a NR contains a dimerization 
interface and a surface to interact with co-activator and co-repressor proteins. The 
RAR/RXR heterodimer has much more efficiency of binding to cognate response 
elements than either RAR or RXR homodimers.10 In the absence of ligand, RAR can 
heterodimerize with RXR and bind to RARE in complex with a co-repressor protein.3 
Binding of an agonist to RAR induces a conformational change so that the receptor 
structure becomes more compact.8 This results in dissociation of the co-repressor and 
recruitment of a co-activator protein for transcriptional regulation.3 AF-2 is responsible 
for this conformational change.15 In contrast, antagonists could interfere with the 
formation of the active receptor conformation, and then the interaction with co-
activators.8  
 
 6 
 
(Figure 1-4. Continues on next page) 
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Figure 1-4. Full sequence alignment of the three isotypes of hRARs (hRARα, β and γ or hRARA, B 
and G) and the three hRXRs (hRXRα, β and γ or hRXRA, B and G). The numbering scheme along 
the top of the sequences shows every tenth (*) and twentieth (number) space.  The register for the 
individual sequences is shown at the right side of a row. The DNA-binding domain (DBD) is boxed in 
green and the ligand-binding domain (LBD) is boxed in blue. The conserved sequences are 
highlighted in dark pink (completely conserved; 6 out of 6), blue (highly conserved; 5 out of 6) and 
dark purple (less conserved; 4 out of 6).  A gap in the alignment is shown with a dash (-).  The 
alignment was performed with the program Clustal X16 and displayed with GeneDoc17.  
 
 
The different isotypes of retinoic acid receptor correspond to different drug 
targets and perform specific functions. For example, acute promyelocytic leukemia 
(APL), a subtype of acute myelogenous leukemia (AML), is associated with 
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chromosomal translocations involving RARα. This translocation produces the PML 
(promyelocytic leukemia)-RARα fusion protein. The expression of this protein then 
results in the induction of APL.18,19 RARβ acts as a potential tumor suppressor2 in growth 
of different cell types and might be a key factor in the anti-proliferative effect of 
retinoids.12,20 RARγ is involved in skin photo-aging and carcinogenesis, and in skin 
diseases like psoriasis and acne.21 A sequence alignment (see Figure 1-5) shows all but 
three residues in the ligand-binding pockets (LBPs) of RARs are conserved.21 This 
implies that the three different residues of the LBP, which are located in α-helices H3, 
H5 and H11,12 are involved in differentiating the specificity of the RARs between 
retinoids (see Table 1-1). (The numbering system for the α-helices of RARs was named 
according to the similarity to the crystal structure of RXRα.13) Among retinoic acid 
receptors, RARγ occurs in nearly all tissues and is the most important RAR for regulation 
of the rate of retinoic acid turnover and retinoic acid induced growth inhibition.22 
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Figure 1-5. Sequence alignment of the LBD of hRARα (hRARA; amino acids 154-462), hRARβ 
(hRARB; amino acids 146-448) and hRARγ (hRARG; amino acids 178-423). Amino-acid numbering 
in the alignment is for hRARγ, which means amino acids located at the same column may not have 
the same number in the other isotypes. The labeled α-helices and β-strands are boxed in orange and 
purple, respectively. The three hRAR isotype-specific residues in the LBP are indicated with red 
highlight (Table 1-1).  The activation domain of AF-2 is highlighted in yellow-green. The dark green 
shadowed sequence shows completely conserved sequences (3 out of 3); The dark purple highlighted 
sequence shows highly conserved sequences (2 out of 3); The sequence column with the white 
background indicates non-conserved sequences. The alignment was performed with the program 
Clustal X16 and displayed with GeneDoc17.  
 
RAR Isotype α-helix 3 (H3) α-helix 5 (H5) α-helix11 (H11) 
RARα Ser232 Ile270 Val395 
RARβ Ala225 Ile263 Val388 
RARγ Ala234 Met272 Ala397 
 
Table 1-1. Comparison of residues located at α-helices H3, H5 and H11 (see residues highlighted in 
red for the alignment in Figure 1-4) among different RAR isotypes.   
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Retinoids are commonly used in medicine since they exert pleiotropic effects on 
regulating biological processes such as cell growth, differentiation, apoptosis, embryo 
development, angiogenesis, metastasis and immune function.23 Vitamin A deficiency 
(VAD) can cause eye disorders, skin disease, growth retardation in children and 
vulnerability to urinary and respiratory infections. Furthermore, retinoids play an 
important role in the therapy and prevention of cancer by interacting with RARs and 
RXRs, which are ligand-dependent transcription regulators. Retinoids are well known as 
one of the most promising classes of cancer chemoprevention agents. Generally, 
apoptosis is not induced by single retinoid agents but can be enhanced by retinoids 
combined with DNA damaging agents.23 The most impressive example of anticancer 
activity of retinoids is the treatment of APL by T-RA [3].12,24 Taking advantages of 
receptor specificity, synthetic retinoids have been developed to enhance their anti-
proliferative activity and have shown promise as chemotherapy agents. For example, 
polyprenoic acid [11] (see Figure 1-6), an acyclic retinoid (ACR), can inhibit the growth 
of hepatoma cells in vitro and in vivo25 and also prevent the development of recurrent or 
second primary hepatocellular carcinoma.26 Another example is fenretinide (4-HPR) [12] 
(see Figure 1-6), which has shown reduction of secondary breast cancers27 and primary 
ovarian cancers.28 (The term “second primary” in cancer refers to a new primary cancer 
in a person with a history of cancer.29 The term “secondary cancer” is used to describe 
either a new primary cancer or cancer that has spread from the place in which it 
originated to other parts of the body.29) 
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However, the clinical effectiveness of natural retinoids and some synthetic 
retinoids is limited by their significant toxicities.30,31 The term “hypervitaminosis A” 
refers to the toxicities that accumulate with chronic retinoid treatment, and its effects are 
observed in skin, hair, eyes, liver, and bones of the body. Early research from the 1980s 
to develop retinoid analogs, like arotinoids, focused on structure modifications of the 
polyene side chain with inclusion of an aryl ring. The compound TTNPB [13] (see Figure 
1-6) is a representative example. TTNPB [13] is 10-fold more potent than T-RA [3] in the 
tracheal organ culture (TOC) differentiation assay and equally effective in the ornithine  
 
                                 
          11  Polyprenoic acid                                                                              13  TTNPB         
                          
 
12  Fenretinide (4-HPR) 
Figure 1-6. Example of synthetic retinoids as chemoprevention agents 
 
decarboxylates (ODC) induction assay.23 But in clinical application, this compound is 
prohibited because of its 10,000-fold greater toxicity than T-RA [3].23 To reduce the 
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toxicity of arotinoids, an oxygen or sulfur heteroatom was added into the cyclic ring to 
block metabolic oxidation of the compounds.23 This is how the heteroarotinoids [14] (see 
Figure 1-7) were designed to improve the therapeutic ratio (efficacy/toxicity) as anti-
cancer agents. Tazarotene [15] (see Figure 1-7), a heteroarotinoid with a sulfur 
heteroatom in the cyclic ring, has shown promise in clinical applications with a good 
safety profile.  
                              
R=R’=R’’=H, Alkyl, OAlkyl 
X=N-Alkyl, O, S 
Z=NO2, CO2Alkyl, CO2H, SO3Alkyl 
LG=Linking Group 
14  Typical heteroarotinoid with biological activity                             15  Tararotene  
Figure 1-7. 
 
A new class of Flexible Heteroarotinoids (Flex-Hets) (see Figure 1-8), which 
contains a 3-atom thiourea [16] or urea [17] linker, exhibited improved therapeutic ratios 
as anti-cancer agents in comparison with natural retinoids.31,32 The heteroarotinoid with a 
thiourea or urea linker becomes more flexible and was better accommodated in the RARγ 
receptor ligand-binding domain.33 In addition to regulating growth and differentiation 
similar to RA, Flex-Hets induced potent apoptosis in ovarian cancer and in head and neck 
squamous cell carcinoma (HNSCC) through a mitochondria-dependent pathway.24-27  
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             16  SHetA2                                                                        17  SHetC2 
Figure 1-8. Flex-Hets: SHetA2 and SHetC2 
 
 
 
Among Flex-Hets, the lead compound SHetA2 [16] (1-(2,2,4,4-tetramethyl- 
thiochroman-6-yl)-3-(4-nitrophenyl) thiourea) exhibited significantly potent activity and 
lack of toxicity across all cell lines tested in vitro and in vivo.34 The latest research shows 
the optimal structure of Flex-Hets for enhancing potency is made up of a urea linker, a 
NO2 substitution and a flexible thiochroman unit.33 Compared to SHetA2, a new Flex-Het 
compound SHetC2 [17] (1-(2,2,4,4-tetramethylthiochroman-6-yl)-3-(4-nitrophenyl) 
urea), which contains a urea linker instead of a thiourea linker, exhibited increased 
activity with a similar mechanism of induction of apoptosis while keeping the same 
therapeutic ratio.33 The compound structures of SHetA2 [16] and SHetC2 [17] are 
specifically designed and synthesized for hRARγ selectivity. The goal of this research is 
to obtain recombinant hRAR LBD and determine the X-ray crystal structures of the LBD 
in complex with SHetA2 [16], SHetC2 [17], and other heteroarotinoids and explore how 
these synthetic heteroarotinoids interact with hRARγ. This information will be used to 
enhance the understanding of the binding pocket of the hRAR LBD and how it can adapt 
to different drug targets. Atomic resolution of the heteroarotinoid interactions with the 
receptor will aid in optimization of the drugs conformation and functional groups. To 
approach this goal, a highly pure and concentrated protein solution is inevitably 
necessary. The development of molecular cloning techniques allows almost any protein-
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encoding gene to be isolated from its parent organism and to be expressed at high levels 
in a microorganism.1 The recombinant protein, which accumulates to high levels and 
constitutes a high percentage (up to 40%) of the total cell protein, is far easier to isolate 
than it would be from its parent organism, in which it may occur in small or trace 
amount.1 We have successfully cloned the gene of hRARγ LBD and have efficiently 
obtained the recombinant protein expressed with a poly-histidine tag. The preliminary 
crystallization trials of hRARγ LBD in complex with T-RA [3] are underway to check the 
integrity of the construct and to establish a lead crystallization condition. Those 
experimental details are reported in Chapter II (Methodology). So far, small crystals have 
been obtained and await characterization by X-ray diffraction.  
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CHAPTER II 
 
 
METHODOLOGY 
 
2.1     Introduction 
 
The retinoic acid receptors (RARs) and the retinoid X receptors (RXRs) belong to 
the nuclear receptor family, which act as transcriptional factors. The regulation of gene 
expression by RARs or RXRs is ligand-dependent. The crystal structure of the hRARγ 
LBD bound to T-RA has been determined at a resolution of 2.0 Å by Renaud et al. in 
19959 (Protein Data Bank (PDB) code: 2LBD; see Figure 2-1). 
 
The LBD of hRARγ is made up of eleven α-helices (H1, H3-H12), two β-strands 
(S1 and S2) and two Ω-loops.9 The lack of α-helix H2 in the structure of the hRARγ 
LBD is due to consideration of the numbering method in comparison with the crystal 
structure of hRXRα9 where there is an extra helix between the H1 and H3 helices as 
revealed when the similar structures are superimposed. The hRARγ LBD structure 
exhibits an anti-parallel α-helical sandwich8 in which the ligand-binding pocket (LBP) is 
formed for ligand binding. The α-helices H4, H5, H6, H8 and H9 stay in the center of 
this three-layer structure with H1 and H3 on one side, and H7, H10 and H11 on the other 
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side.9 The ligand-dependent activation function 2 (AF-2) is located on H1212 and 
determines the binding of different ligands.  The crystal structure shows that the binding  
 
 
                                                         (a)                                                   (b) 
Figure 2-1. A ribbon diagram of the hRARγ LBD bound to all-trans retinoic acid.9 The LBD model is 
colored in a rainbow gradient from the N-terminus (red) to the C-terminus (violet). T-RA is shown as 
a ball-and-stick model in white, the α-helices are depicted as coils, and the β-strands as arrows. The 
α-helices, β-strands and Ω-loop are labeled. (a) A view of the hRARγ LBD structure. (b) The view at 
+150° rotation of (a).  
 
of T-RA [3] can be explained by the electrostatic guidance mechanism proposed by 
Renaud et al.9 The negatively charged ligand is attracted into the LBP by a positively 
charged amino acid cluster8 in hRARγ. The ligand-induced conformational change of 
hRARγ LBD occurs with the refolding of the Ω-loop and α-helix H12.8 The highly 
selective hydrophobic and hydrophilic regions in the hRARγ LBP makes possible the 
maximum activation by a ligand.35 The hRARγ LBD is monomeric in solution, with or 
without the presence of a ligand.9 
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Among the RAR isotypes, the sequences are highly conserved. In the LBP there 
are three residues that are changed between the three isotypes.21 This suggests the 
mechanism for the different selectivity among the RAR isotypes. For example, formation 
of hydrogen bonds between an amino group in the RARα selective ligands and the 
RARα-specific Ser232 residue favors RARα selectivity.12 This is because no such 
hydrogen bond forms in RARβ or γ LBPs, which consist of an Ala instead of a Ser.12 The 
prerequisite for RARγ selectivity is that the hydroxyl group of RARγ selective retinoids 
forms a hydrogen bond to the sulfur atom of Met272 in  RARγ.21 The hydroxyl group 
reduces the affinity of ligands, but the formation of this hydrogen bond helps regain some 
of the binding.21 Figure 2-2 shows an example of hydrogen bonds between RARγ and a 
synthetic retinoid molecule BMS184394 [18] (6-[hydroxy-(5,5,8,8-tetramethyl-5,6,7,8-
tetrahydro-naphtalen-2-yl)-methyl]naphtalene-2-carboxylic acid) from the co-crystal 
structure of this compound with the LBD (PDB code: 1fcx).21 Note the hydrogen bond 
between the hydroxyl group of BMS184394 and Met272 of RARγ LBD.  
 
RARγ plays an essential role in mediating topical retinoid efficacy and irritation 
associated with the use of retinoids in animal models.36 RARγ in human epidermis 
preferentially traps T-RA [3] as its ligand rather than 9C-RA [5] under physiological and 
pharmacological conditions.37 T-RA [3] will be used as the ligand in the preliminary co-
crystallization trial to check the integrity of the construct through examination of the 
complex by X-ray analysis. 
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(a)  18  BMS184394 
 
 
 
 
 
(b) 
 
Figure 2-2.  (a) Synthetic retinoid BMS184394. (b) A view of the RARγ LBP in complex with 
BMS184394. The formation of a hydrogen bond between the hydroxyl group (red) of BMS184394 
(green backbone) and the sulfur atom of Met272 (yellow) of RARγ (white backbone) is shown by a 
white dotted line.   
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2.2 Materials and Methods 
 
2.2.1 Genetic engineering of hRARγ LBD 
The general experimental outline of genetic engineering includes three major 
steps: isolation, insertion into a vector and transformation.38 Usually, a gene of interest (a 
segment of DNA) can be obtained from cDNA (complementary DNA) or gDNA 
(genomic DNA) libraries and amplified using polymerase chain reaction (PCR) 
techniques. The isolated gene is cloned into a vector, such as a plasmid or a viral vector. 
The construct then is used to transform target organisms (such as virus, prokaryotes and 
eukaryotes), which depends on the type of vector used.  Finally, the recombinant gene 
which is isolated from the transformant culture will be expressed into functional gene 
product, i.e., protein. Experimentally, a sterile environment is an extremely important 
factor to guarantee correct results. Before carrying out the experimental protocols, we 
always sterilized all experimental bench space, instruments, appliances and DI water by 
Amphyl disinfectant (Reckitt Benckiser), ethanol, bleach or autoclaving (Electric 
Pressure Steam Sterilizer 25X, maximum temperature: 126°C; maximum pressure: 20 
psi; All-American). For safety, Amphyl disinfectant, ethanol or bleach was used for 
different waste handling. 
 
2.2.1.1 Isolation and PCR  
The full-length hRARγ cDNA (Clone ID IOH14052, corresponding to GenBank 
NM000966.3, Invitrogen) was obtained as a part of a pENTR221 plasmid in Escherichia 
coli (see Figure 2-3). The plasmid (with a kanamycin-resistant gene for selection) was  
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Figure 2-3.  The gene map of the pENTR221 plasmid (Invitrogen). A cDNA containing the full-length 
hRARγ gene (blue region) was obtained as part of pENTR221 plasmid. 
 
 
isolated at room temperature by the Wizard Plus SV Miniprep DNA Purification System 
(Promega). The procedure was to take a fresh Luria-Bertani (LB) agar plate with 50 
µg/ml kanamycin and streaking it with frozen E. coli stock which contains the 
pENTR221 plasmid. The E. coli colonies were produced on the plate, which was placed 
in an inverted position, with overnight incubation at 37°C. A 10 ml volume of LB 
medium containing 50 µg/ml kanamycin was placed in a 50 ml conical tip tube and 
inoculated by a single, well-isolated E. coli colony (selected using a sterile toothpick) and 
grown with shaking (200 rpm, Max Q 500 shaking incubator, Barnstead Lab-line) for 16 
hours at 37°C in a vertical position. The cells were harvested by centrifugation (Allegra 
X-15R Benchtop Centrifuge, Beckman Coulter) of the bacterial culture at 4500 rpm for 
10 min at 4°C. The supernatant was discarded. The cell pellet was resuspended 
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completely in 250 µl Cell Resuspension Solution (50 mM Tris-HCl pH 7.5, 10 mM 
EDTA, and 100 µg/ml RNase A) by vortexing. Afterwards, the resuspended pellet was 
transferred into a 1.5 ml microcentrifuge tube and mixed with 250 µl Cell Lysis Solution 
(0.2 M NaOH and 1% SDS) by inverting the tube 4 times. Partial clearing of the lysate 
was observed after 5 min incubation. To quench the endonucleases and other proteins 
released during the lysis, Alkaline Protease Solution (10 µl) was added into the lysate, 
mixed by inverting the tube 4 times and incubated for 5 min. After incubation, the cell 
solution was mixed with 350 µl Neutralization Solution (4.09 M guanidine 
hydrochloride, 0.759 M potassium acetate, and 2.12 M glacial acetic acid) by inverting 
the vial 4 times for solution neutralization. The mixture was centrifuged (Marathon 
Microcentrifuge, Fisher Scientific) at maximum speed for 10-30 min until the cell debris 
was pelleted. The cleared lysate then was decanted into a Spin Column, which was 
inserted into a 2 ml Collection Tube for the plasmid DNA purification. The contents in 
the Spin Column were centrifuged at maximum speed for 1 min, and the flowthrough 
from the Collection Tube was discarded. The Column Wash Solution (750 µl, 60% 
ethanol, 60 mM potassium acetate, 8.3 mM Tris-HCl, 0.04 mM EDTA) was added into 
the Spin Column and centrifuged at maximum speed for 1 min, and the flowthrough was 
discarded. Ethanol will precipitate the plasmid DNA, which was collected by the resin of 
the Spin Column. The wash was repeated using 250 µl Column Wash Solution and 
centrifuged for 2 min at maximum speed. The Spin Column was transferred to a new 1.5 
ml microcentrifuge tube. By adding 100 µl Nuclease-Free water into the column with 1 
min centrifugation at maximum speed, the plasmid DNA was eluted into the 1.5 ml 
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microcentrifuge tube. The Spin column was discarded, and the plasmid DNA samples 
were stored at -20°C until processed. 
 
 The fragment of human retinoic acid receptor consisting of the hRARγ LBD was 
amplified from the full-length hRARγ cDNA (Invitrogen) by PCR (AccuPrime Taq DNA 
Polymerase System, Invitrogen; PTC-150 Minicycler, MJ Research) with primers 
(Invitrogen) RARG 1F 5’-CAC CGA CAG CTA TGA GCT GAG CCC-3’ and RARG 
1R 5’-CTC AAA CAT TTC AGG GTT CTC C-3’. Each of the primers was diluted to the 
concentration of 20 µM before PCR setup. In each 100 µl PCR mixture (10 µl of 10X 
AccuPrime PCR buffer II, 1 µl of 20 µM forward primer, 1 µl of 20 µM reverse primer, 1 
µl of Taq DNA polymerase solution, 2 µl or 4 µl of the isolated plasmid), after 2 min 
initial denaturation at 94°C, each of 30 PCR cycles included the following steps: 30 
seconds denaturation at 94°C, 30 seconds annealing at 55°C and 1 min extension at 68°C. 
The final extension was allowed to go for 5 min at 68°C.  
 
The PCR product (738 bp) was loaded onto a 1% agarose gel (total of 4 lanes) 
containing 0.5 µg/ml ethidium bromide and verified through agarose gel electrophoresis 
(100 V, 2 hrs, Sub-Cell GT agarose gel electrophoresis, BioRad). The bands 
corresponding to the correct size of the PCR product were visualized under UV light. To 
purify the PCR product, the Invitrogen PureLink Quick Gel Extraction Kit was used. This 
purification procedure removes primers, nucleotides, enzymes, mineral oil, salts, agarose, 
ethidium bromide, and other impurities from DNA samples. The bands containing the 
PCR product were cut from the gel and divided into two 1.5 ml microcentrifuge tubes to 
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dissolve the gel material. The Gel Solubilization Buffer (644.7 µl) was added into the 
tube which contained 214.9 mg of the excised gel slice. The other tube contained 246.5 
mg of gel slice so that 739.5 µl of Gel Solubilization Buffer was added. The tubes were 
incubated at 50°C for 15 min with mixing every 3 min. An additional 5 min incubation at 
50°C was done to ensure that the gel completely dissolved. The solutions were pipetted 
respectively into two Quick Gel Extraction Columns, which were placed onto the Wash 
Tubes, and centrifuged in the microcentrifuge for 1 min at maximum speed. The 
flowthrough was discarded. Wash Buffer (700 µl) containing ethanol was added into each 
of the Spin Column. After 5 min of incubation at room temperature, the solutions were 
centrifuged for 1 min at maximum speed, and the flowthrough was discarded. After one 
more round of centrifugation to assure removal of all liquid, the columns were transferred 
onto new 1.5 ml Recovery Tubes. The Nuclease-Free water (50 µl) was then added into 
each of the columns, and the PCR products bound to the resin of the columns were eluted 
into the Recovery Tubes. This gel-purified PCR product will be used for the cloning step 
or stored at -20°C. According to the band intensity comparison between the PCR product 
and the DNA mass ladder (Invitrogen), it was known that the concentration of the gel-
purified PCR product is between 10 ng/µl and 14 ng/µl.  
 
2.2.1.2 TOPO cloning reaction of PCR product  
 Following PCR amplification of the gene, the hRARγ LBD PCR product with the 
“CACC” sequence at the 5’-end was directionally cloned into TOPO pET100/D vector 
(Champion pET Directional TOPO Expression kits, Invitrogen) in frame with the N-
terminal tag (see Figure 2-4). The “CACC” sequence gave the PCR product an end that 
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was complementary to the “sticky end” of the plasmid, whereas the other end was blunt 
without sequence complementarity.  This was designed to increase the chances that the 
insert was cloned in the correct orientation. The pET100/D vector contained an 
ampicillin-resistant gene for selectivity and provided expression of recombinant protein 
with a poly-histidine (His) tag and an enterokinase (EK) recognition site in the N-
terminus (see Figure 2-5). The poly-His tag would allow for purification of the fusion 
protein with a more convenient and efficient method, i.e. nickel(II) chelate affinity 
chromatography, followed by gel filtration chromatography. The EK recognition site 
would provide the option to remove the N-terminal tag with enterokinase. 
 
 
 
 
Figure 2-4.  A PCR product with a “CACC” 5’ end (blue highlight) was inserted into a vector of 
pET00/D by TOPO directional cloning (Invitrogen). 
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Figure 2-5.  The gene map of the pET100/D-TOPO vector (Invitrogen). The plasmids are linearized 
by Topoisomerase I and become circularized upon insertion of a PCR product containing a 5’ CACC 
overhang. 
  
 
To perform the TOPO cloning reaction, 4 µl of fresh PCR product, 1 µl salt 
solution and 1 µl TOPO pET100/D vector were added into a 0.5 ml microcentrifuge tube, 
mixed gently, and incubate for 30 min at room temperature. The reaction was then placed 
on ice to proceed to transformation. The hRARγ LBD was propagated on either E. coli 
strain TOP10 (Invitrogen) or E. coli BL21 Star DE3 cells (Invitrogen) in LB plates or 
medium containing 200 µg/ml ampicillin for selection of transformants and expression 
experiments. The optimal growth temperature was 37°C. The hRARγ LBD/pET100/D 
construct (4 µl of TOPO cloning reaction) was added into one vial of competent TOP10 
cells (Invitrogen) and gently mixed. The solution was incubated on ice for 30 min. The 
cells were heat-shocked for 30 seconds at 42°C without shaking and transferred back on 
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ice immediately. The room temperature SOC medium (250 µl) was added into the vial to 
provide sufficient nutrition to help cell propagation. The vial was capped tightly and 
incubated with shaking (200 rpm) at 37°C for 1 hour. Then, using a bent glass rod, 150 µl 
of the transformant was spread on a pre-warmed (37°C) agar plate containing 200 µg/ml 
ampicillin and was incubated overnight at 37°C. Into each of six 15-mL conical bottom 
vials, 12 ml of pre-warmed LB medium was added, and each was inoculated with a single, 
well-isolated colony picked from the overnight incubated plate and grown with shaking 
(200 rpm) overnight at 37°C. An aliquot (1.5 ml) of the overnight cell culture was mixed 
gently with 0.5 ml of a sterile 60% glycerol solution in a 2 ml cryo-vial and stored at        
-80°C for future propagation and maintenance of gene construct. The remaining media 
from the cultures were isolated by the Wizard Plus SV Miniprep DNA Purification 
System as previously described.  
 
To pick the right plasmid DNA with the correct insertion, the isolated plasmid 
DNA (hRARγ LBD/TOPO pET100/D) (~10 ng/ml) was digested by the restriction 
enzyme SacI (Promega). In each of the 0.5 ml microcentrifuge tubes (total of six), 14.8 µl 
of sterile water, 2 µl of RE 10x buffer, 0.2 µl acetylated BSA, 4 µl isolated plasmid DNA 
and 1 µl of the Sac I solution were added and incubated at 37°C for 2 hrs. After running 
the protease-treated samples through agarose gel electrophoresis with the undigested 
plasmid DNA as a negative control, the integrity of the plasmid DNA was checked to 
confirm that the hRARγ LBD gene was cloned into the pET100/D vector with the correct 
size and orientation. The DNA fluorescent sequencing with T7 promoter and terminator 
primers, which control the expression from the plasmid, was performed by the 
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Recombinant DNA/Protein Resource Facility of the Biochemistry and Molecular Biology 
department to confirm the construct was in frame with the appropriate N-terminal fusion 
tag. Later, the correct isolated plasmid DNA (3 µl) with a concentration of 10 ng/µl was 
transformed into BL21 Star DE3 cells using the same protocol as that of transforming 
TOP10 cells. Without plating, the transformant was directly used for cell culturing.  
 
2.2.2 Protein expression and purification 
A 10-ml sample of LB medium with 200 µg/ml ampicillin was inoculated with 
hRARγ LBD/pET100/D TOPO-transformed E. coli BL21 Star (DE3). The cell culture 
was grown overnight at 37°C with shaking (225-250 rpm) until an optical absorbance of 
the culture, measured at 600 nm (A600), was equal to between 1 and 2. The entire 
overnight culture was used to inoculate 200 ml LB media containing 200 µg/ml 
ampicillin. Cells were grown at 37°C with shaking (225-250 rpm). Once the absorbance 
(A600) was about 0.6 (about 3 h), the incubator’s temperature was changed from 37°C to 
25°C. Then the expression of the recombinant protein was induced by 1 mM isopropyl β-
D-1-thiogalactopyranoside (IPTG) (Sigma), and the bacteria were incubated with shaking 
for an additional 3 to 4 h at room temperature until a final absorbance of A600 = 1.3. Cells 
were harvested by centrifugation (Allegra X-15R Benchtop Centrifuge, Beckman Coulter) 
at 4500 rpm for 10 min at 4°C. The supernatant was discarded and the pellets were frozen 
and kept at -80°C until needed.  
 
Part of the hRARγ LBD purification and crystallization protocol followed the 
procedure described by Natacha Rochel, et al.39 It was modified to find the most 
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appropriate conditions for this particular construct. The cell pellet from the 400-ml 
culture was fully resuspended in 10 ml ice-cold buffer (5 mM imidazole, 500 mM NaCl, 
20 mM Tris HCl pH 8.0). After addition of 100 mg/ml of lysozyme, the cells were 
incubated for 30 min on ice and 5 min at 42°C. The lysate was sonicated (Sonifier 150 
Liquid Processor, Branson) for 1 min at analog speed setting of “3” (about 540 rpm) 
followed by cooling on ice for 1 min. The sonication/cooling steps were repeated twice 
more until the lysate was no longer viscous. During the optimization for the expression of 
the hRARγ LBD recombinant protein, it was discovered that the protein was soluble. 
Using the uninduced bacteria as a negative control, a protein band from induced bacteria 
corresponding to the expected size (~30 kDa) of hRARγ LBD was seen on 15% sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gels using coomassie 
brilliant blue staining (see Figure 2-8 and 2-10). Electrophoresis was carried out using a 
Mini-PROTEAN 3 Cell (BioRad). After sonication, the cell debris was pelleted by 
centrifugation at 4500 rpm for 30 min at 4°C in an Allegra X-15R Benchtop Centrifuge 
(Beckman Coulter). The supernatant was transferred into a 10 ml conical tip centrifuge 
tube and centrifuged 3 or more hours until a clear crude extract was obtained. 
 
To confirm that the overexpressed band was the desired protein, a Western blot 
was performed using an alkaline phosphatase (AP)-conjugated antibody (Anti-HisG-Ap, 
Invitrogen). This antibody specifically detects the 6x histidine tag. The samples of crude 
extract were run through an SDS-PAGE gel (15%), and then soaked in cold running 
buffer (20% methanol, 25 mM Tris pH 8.3, 192 mM glycine) for 15 min at 4°C. A 
sandwich containing a fiber pad, filter paper, the SDS-PAGE gel, a nitrocellulose 
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membrane, a second piece of filter paper, and a second fiber pad was assembled. The 
sandwich was placed in the Western blot apparatus with an ice block, a stir bar, and cold 
transfer buffer (25 mM Tris-HCl pH 8.3, 192 mM glycine, 20% (v/v) methanol) filled 
container. The protein was transferred onto the nitrocellulose membrane 
electrophoretically at 100 V for 1 hour. Stirring was continued during the run to evenly 
mix the solution. After electrophoresis, the nitrocellulose membrane was removed from 
the sandwich and soaked in 10 ml of blocking solution (5% nonfat dry milk mixed with 
PBS solution containing 137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4·7 H2O and 1.4 
mM KH2PO4, pH 7.5) with gentle agitation on a rocker platform for 1 hour. For best 
results, the following steps were all done with gentle agitation. The membrane was 
washed with 20 ml TBST (20 mM Tris-HCl, 140 mM NaCl, pH 7.5, 0.1% Tween-20) for 
5 min and repeated two more times.  The membrane was then transferred into a 10 ml 
dilution buffer (TBST solution with 1% nonfat dry milk and 2 µl of the AP-conjugated 
antibody) and incubated overnight. The membrane was moved into 20 ml of TBST and 
washed for 5 min and repeated three additional times. The membrane was washed in 20 
ml of TBS (20 mM Tris-HCl, 140 mM NaCl, pH 7.5) for 5 minutes to remove detergent. 
After another two rinses in 20 ml alkaline phosphate buffer (100 mM diethanolamine, 
100 mM NaCl, 5 mM MgCl2, pH 9.5), the membrane was transferred to 10 ml of the 
alkaline phosphate buffer containing 33 µl of a 50 mg/ml BCIP (5-bromo-4-chloro-3'-
indolyphosphate p-toluidine salt) solution and 330 µl of a 10 mg/ml NBT (Nitro-Blue 
tetrazolium chloride) solution, and the color was allowed to develop.  The recombinant 
protein was shown on the membrane as purple bands at the correct size (see Figure 2-9). 
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The color development was stopped by washing with DI water, and the membrane was 
air-dried.  
 
The Biologic Duoflow Chromatography System (BioRad) was used for 
purification of hRARγ LBD recombinant protein. The nickel(II) chelate affinity 
chromatography was performed as the first step of the purification protocol because the 
engineered protein contained a poly-His tag in the N-terminus. Since proteins without 
this tag do not bind to the nickel metal ion, or bind only weakly, they were eluted first. 
Therefore, it is possible to separate proteins with the tag from those without the tag by 
gradually increasing the imidazole concentration during the elution step.  
 
By the use of ampicillin antibiotics, β-lactomase, which was encoded in the 
ampicillin resistant gene, was produced in substantial amounts during culturing. The β-
lactomase could not be washed out of the column by using the same condition as most of 
the other non-specific proteins in the crude extract were. The stepwise purification 
protocol was optimized after a purification run using a linear gradient method. A nickel(II) 
chelate column with a 5-ml bed volume (HisTrap HP, GE Healthcare) was equilibrated 
with 10 column volumes of binding buffer (5 mM imidazole, 500 mM NaCl, 20 mM Tris 
HCl pH 8.0) at a flow rate of 5 ml/min. The clear crude extract (10 ml) from 400 ml of 
cell culture was preloaded into the column at 1 ml/min, followed by washing with 10 
volumes of elution buffer I (50 mM imidazole, 500 mM NaCl, 20 mM Tris HCl pH 8.0) 
and 12 volumes of elution buffer II (500 mM imidazole, 500 mM NaCl, 20 mM Tris HCl 
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pH 8.0) at 5 ml/min.  The protein of interest, hRARγ LBD (~30 kDa), was eluted with 
200 mM or 500 mM imidazole but β-lactomase was eluted with 50 mM imidazole.  
 
After the fractions that contained the LBD were concentrated (Allegra X-15R 
Benchtop Centrifuge, Beckman Coulter, at 3000 rpm, 4°C) to 1 ml using a 20 ml 
centricon with 10,000 MW cut-off (Vivaspin, Vivascience), the hRARγ LBD sample was 
loaded onto a Superdex 200 10/300GL column for gel filtration chromatography. Adding 
reducing agents, such as 1,4-dithiothreitol (DTT), can prevent the hRARγ LBD protein, 
which contains free Cys residues, from oxidization and degradation.40 The buffer 
containing 10 mM DTT, 500 mM NaCl, 10 mM Tris-HCl pH 8.0, and 0.15 mM n-
dodecyl-β-D-maltoside39 was run through the column at a flow rate of 0.25 ml/min for 
protein washing and elution (see Figure 2-15). The purified recombinant protein hRARγ 
LBD was concentrated (2000 rpm, 4°C, time varies), and the final concentration was 
determined by the Bradford assay using bovine serum albumin as the standard (see 
Figure 2-6). In this method, Coomassie Brilliant Blue G-250 will bind to proteins and 
then obtain absorbance in the visible region (blue color; 600 nm).  The protein 
concentration is proportional to the absorbance and can be calculated based on a 
calibration curve of absorbance vs. concentration.   
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Figure 2-6. Bradford assay. The left solution (brown) without protein acts as a blank. The right 
solution containing hRARγ LBD turns blue after 5 minutes incubation at room temperature. The 
darker blue the solution becomes, the more concentrated the protein solution. 
 
 
2.2.3. Crystallization  
          The process of exploring the three-dimensional structure begins with obtaining 
large, single protein crystals which are suitable for X-ray diffraction. Crystals that diffract 
well and are larger than 100 µm are needed for this purpose.41 A single crystal then is 
mounted in a loop or a capillary tube and placed in an X-ray beam. The diffraction 
pattern is collected (at cryo-temperatures in the case of mounting in the loop) and 
analyzed to obtain the structure of the protein. But it is very difficult to predict the 
optimal condition for protein crystal growth because a number of environmental 
variables, such as protein purity, pH, protein concentration, temperature, precipitants, 
etc., have to be considered.42 A highly purified protein with at least 90-95% purity is a 
prerequisite for the formation of sufficient homogeneity during crystallization. A buffer 
helps stabilize the pH value of the crystallization condition. The addition of precipitants 
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is necessary to promote crystallization of protein from solution. A change of temperature 
makes protein more or less saturated.  
 
In this research, the hanging-drop vapor diffusion method was used (see Figure 2-
7), which is the most frequently reported method for crystallization. In a vacuum grease-
sealed space, the well solution usually consisted of a mixture of buffer, precipitant and 
additives. The droplet hanging on the coverslip is composed of both protein solution and 
well solution. Since the droplet contained precipitate with less concentration than that in 
the well solution, water vapor diffused from the droplet and was transferred to the 
reservoir in the closed space. When the droplet becomes supersaturated,40 spontaneous 
nucleation of the crystals occurs. If the right condition was achieved, which means a 
metastable region (a condition between solubility and supersolubility), the crystal would 
keep growing.40 Since the system would be in equilibrium, the optimum conditions would 
be maintained until the crystallization was complete.42 Usually, crystal screening 
(Hampton Research) is the first step to find the possible conditions for crystallization. It 
is a method of sparse matrix sampling proposed by Jancarik et al.43 The solution and 
precipitate conditions are empirically derived based on known or published 
crystallization conditions of various proteins in the past.43 Once the appearance of micro-
crystals, polycrystalline aggregates, thin plates, etc., has been observed for the protein40 
in the screening, the crystallization conditions should be optimized by small adjustments 
of pH, temperature alteration, or changes in concentration of precipitant and additives.  
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(a) 
 
 
 
(b) 
Figure 2-7. The demonstration of the hanging drop vapor diffusion method (Hampton Research). (a) 
Vacuum grease-sealed experimental setup with a droplet hanging on the inverted coverslip. (b) 
hanging drop, which is usually an equal amount of protein solution and well solution.  
 
 
The purified protein of hRARγ LBD with a poly-His tag (~30 kDa) was used for 
crystallization trials. The co-crystallization of hRARγ LBD and T-RA was used as the 
starting point to check the integrity of our construct against the published crystallization 
condition by Rochel et al.39and Klaholz et al.21 and to establish a methodology and 
comparison point for the investigation of the LBD bound to heteroarotinoids. The poly-
His tag was designed with an EK recognition sequence so it could be removed, if 
necessary, by EK digestion. However, Klaholz et al. observed that the protein became 
unstable after removal of the poly-His tag.21 After purification, the protein was 
concentrated to 2-3 mg/ml and was incubated with 2 equivalents of T-RA (Sigma) (20 
Plastic coverslip 
Crystallization droplet  
(protein /well solution)             
Inverted plastic coverslip placed over the reservoir 
Well of a crystallization 
Well solution 
Vacuum grease Hanging drop 
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mM ethanolic stock solution) overnight at 4°C. Then the complex of hRARγ LBD and T-
RA was centrifuged for 30 min at maximum speed (Marathon Microcentrifuge, Fisher 
Scientific) to remove any precipitate before the crystallization setup. The final protein 
solution contained 10 mM DTT, 500 mM NaCl, 10 mM Tris-HCl pH 8.0, 0.15 mM n-
dodecyl-β-D-maltoside, 2 mM 3-[(3-cholamidopropyl)dimethylammonio]-1-propane 
sulfonate (CHAPS) and 4% glycerol.  Since the reducing agent DTT only remained 
active for 2-3 days in the protein solutions,30 crystallization trials were carried out within 
three days of gel filtration. Crystallization trials were performed at room temperature and 
4°C using the hanging-drop vapor diffusion method in 24-well tissue culture plates. 
 
The 500 µl crystallization well solution was composed of a combination of 100 
mM 1,4-piperazinediethanesulfonic acid (PIPES) (pH 6.5-8.5), 1.0-1.7 M sodium acetate, 
and DI water. Hanging drops (10 µl) were typically formed by pipetting 3, 4, 5, 6, or 7 µl 
of well solution into 7, 6, 5, 4, or 3 µl of protein solution on coverslips, respectively. 
Hanging drops with a volume of 5 µl or 6 µl were also explored.  Meanwhile, the crystal 
screen kits (Hampton research) were tried to find new leads to optimize the 
crystallization conditions. 
 
2.3 Results and discussion 
Finally, the highly purified and concentrated protein solution of hRARγ LBD has 
been obtained and crystallization trials are underway. But it took a long time to get the 
cloning right.  The problem arose with the plasmid containing the sequence in the 
incorrect register, which was caused by the use of a plasmid with, as the company 
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(Invitrogen) explained, “some background”. We obtained a new plasmid. Transformation 
was a very crucial step to guarantee expression of the desired recombinant protein. 
Therefore, to avoid contamination from other non-specific plasmids, the use of gel-
purified PCR product and a sterile experimental environment should be considered at all 
times during cloning.  
 
The fragment of hRARγ LBD contains 738 bp. The molecular weight of the 
recombinant protein fused with a histidine tag is around 30 kDa. The sequence of the 
construct of hRARγ LBD/pET100/D-TOPO matches that of the known DNA of hRARγ 
from the NCBI database completely with the exception of one nucleotide, which causes a 
silent mutation that still produces Gln (the “G” was substituted by “A”: CAG→CAA; see 
Appendices I and II). This change does not affect the constructed LBD amino acid 
sequence.  
 
During the bacterial culturing stage, the addition of 1% or 5% glucose or 
sucrose21 was done to assess production levels in comparison with an experiment without 
sugar added. In these experiments, there did not seem to be more bacteria produced in the 
culture with the addition of sugar. The recombinant protein with a poly-His tag has been 
detected and verified by Western Blot analysis with alkaline phosphatase (AP)-
conjugated antibodies (see Figure 2-8 and 2-9).  
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Figure 2-8.  SDS-PAGE gel shows protein expression of hRARγ LBD over time after IPTG induction. 
There are 10 lanes on the gel.  The first lane shows the size marker. The second lane was loaded with 
blank. From the third to tenth lane, the lanes with odd number were loaded by the sample from the 
culture without sugar addition; the lanes with even number were loaded by the samples from the 
culture with addition of 1% sucrose. There were 4 time points. Samples were taken every one hour 
(two lanes) after induction.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-9.  Verification of the recombinant protein of hRARγ LBD on a nitrocellulose membrane by 
Western blot technique. The Western blot was obtained from an identically run, but unstained, SDS-
PAGE gel as in Figure 2-8. 
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Each stage of expression and purification of hRARγ LBD was analyzed by SDS-
PAGE gel electrophoresis (see Figure 2-10). The protein analysis through MALDI-TOF 
mass spectroscopy confirmed the desired protein obtained (see Figure 2-11). 
 
 
 
 
 
 
Figure 2-10. Coomassie blue-stained SDS-PAGE gel of (His)6-hRARγ LBD at each stage of purification. 
Lane 1: crude extract from non-induced bacteria; Lane 2: crude extract from IPTG-induced bacteria; 
Lane 3: (His)6-hRARγ LBD eluted from the nickel(II) chelate affinity chromatography column; Lane 4: 
(His)6-hRARγ LBD after gel-filtration chromatography (final stage).  
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Figure 2-11.  Result of MALDI-TOF mass spectroscopic analysis for recombinant hRARγ LBD. The 
sample was cut from the band on the fourth lane of the SDS-PAGE gel (Figure 2-10). Top score is 65 
for human retinoic acid receptor gamma LBD (ligand-binding domain, residues 178-423). Protein 
scores greater than 64 are significant (p<0.05). 
 
The following chromatograms (Figures 2-12 through 2-15) show the protein 
purification at different stages with different protocols.  In each chromatogram, the 
relationship of absorbance (280 nm; blue) vs. time (min) or conductivity (mS/cm; red) vs. 
time (min) is displayed. The top horizontal scale shows fraction numbers of the eluted 
solution collected. The change in concentration of imidazole is indicated by the black 
line. The purple line shows the change of pH value during separation. To obtain more 
concentrated protein solution after nickel column, 500 mM imidazole was directly used 
without the elution step with 200 mM imidazole after β-lactomase elution. The 
chromatograms of Figure 2-14 and 2-15 correspond to the protocols currently in use for 
protein purification. In Figure 2-14, the recombinant protein of hRARγ LBD was purified 
with 500 mM imidazole through a nickel(II) column and collected from the fractions 38 
to 48. In Figure 2-15, the protein eluted from gel-filtration without imidazole, was 
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purified and collected from fractions 15 to 17. During the gel-filtration step (see Figure 2-
15), no protein was detected in the third peak by SDS-PAGE electrophoresis. This peak 
should correspond to imidazole elution since imidazole will absorb at 280 nm. Thus, 
without the protein dialysis step, which was used in the purification that Rochel, et al. 
described,39 imidazole can be removed at the gel-filtration stage so that the purified 
protein was ready for crystallization.  
 
 
Figure 2-12.  Purification of the hRARγ LBD through nickel(II) chelate affinity chromatography 
using a linear gradient method where the imidazole concentration is gradually varied from 5 to 500 
mM.  
β-lactomase Flowthrough 
hRARγ LBD 
 41 
 
Figure 2-13.  Purification of the hRARγ LBD through nickel(II) chelate affinity chromatography by a 
stepwise purification method. The crude extract was preloaded and washed with 5 mM imidazole. 
The target protein was eluted with 200 mM and 500 mM imidazole. 
 
 
 
Figure 2-14. Purification of the hRARγ LBD through nickel(II) chelate affinity chromatography by a 
stepwise purification method.  The target protein was eluted only with 500 mM imidazole.    
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Figure 2-15. Purification of hRARγ LBD by gel-filtration chromatography. In the flowthrough 
solution, there are non-specific proteins with small amount of the protein hRARγ LBD which 
detected by SDS-PAGE.  
 
The yield of the purified recombinant protein is measured by the Bradford 
method. For a 750-ml culture, about 4 mg of purified protein is obtained and ready to be 
used in crystallization. After gel-filtration, the protein of the hRARγ LBD is about 4/5 
less than that of the one out of the nickel (II) chelate resin. This is not only because of the 
removal of impurities during the gel-filtration stage, but also because of two more 
reasons. Part of the recombinant protein becomes denatured during purification and has 
to be removed by centrifugation due to its loss of biological activity. Also, some protein 
sticks to the centricon membrane in the concentration procedure so that not all of the 
protein is completely recovered.  Those factors should be considered to optimize the 
purification condition and improve the yield of purified protein with biological activity. 
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hRARγ
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The crystal screening was done by using the screen kits HR2-110 containing 50 
conditions, HR2-112 containing 48 conditions, and Index containing 96 conditions 
(Hampton Research). A few very small crystals of hRARγ LBD complexed with T-RA 
with good three-dimensional structure and sharp edges were observed by using a well 
solution containing 0.1 M cadmium chloride hydrate, 0.1 M sodium acetate trihydrate 
(pH 4.6) and 30% v/v polyethylene glycol 400 (No. 34, Crystal Screen 2, HR2-112) at 
room temperature. From the crystallization condition optimized from the literature,39 
some larger but thinner crystals always grew in 2-3 days under pH 7.0 at either 4°C or 
room temperature. None of the crystals diffracted X-rays at medium to high resolution to 
warrant the collection of data or even to obtain the crystal space group. To obtain crystals 
with high quality, there are three ways that could be helpful. First, increase the 
concentration of protein (such as 5 mg/ml) for crystallization because proteins possibly 
form aggregates more easily in dilute solution making it hard to crystallize.40 Second, 
optimization of crystallization conditions based on the screen results need to be done by 
small adjustments of pH and concentration of salts or precipitant. Third, microseeding 
techniques are worth exploring to improve the quality of the crystals as well as promote 
growth of single crystals. For the future work, improved crystals of hRARγ LBD in 
complex with T-RA [3] are desired. If the integrity of the hRARγ LBD construct can be 
proven through structural analysis based on X-ray crystallography, the construct should 
be used to co-crystallize with SHetA2, SHetC2, and other heteroarotinoids to better 
understand the interaction between hRARγ and retinoid ligands so as to help improve 
drug design. 
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CHAPTER III 
 
 
CONCLUSION 
 
The hRARγ plays an essential role in the modulation of the retinoid-induced 
therapeutic benefits in the skin and the retinoid-induced skin irritation.36 Flex-Hets with a 
flexible amide linker and a sulfur atom fused ring are very important for RARγ receptor 
activation and for biological activity. Recent research shows that heteroarotinoids exhibit 
very low toxicity while keeping their therapeutic promise in tissue and in animal 
models.23,31-33 This is very critical for drug design. X-ray analyses of single crystals of 
various heteroarotinoid-RARγ complexes will provide more information and details of 
the RARγ selectivity and on the impact of ligands in the RARγ LBP. Taking advantage of 
the binding properties of the protein will lead to additional and improved drug 
development. This is the ultimate goal of our research. 
 
The hRARγ LBD fragment (residues 178-423) has been successfully cloned into 
pET 100/D vector and overproduced with high efficiency using the TOPO E. coli/T7 
system. This work demonstrates the feasibility of production of recombinant hRARγ 
LBD fusion construct by the TOPO system.  The highly pure recombinant protein of 
hRARγ LBD with a poly-His tag was obtained via nickel (II) chelate affinity 
chromatography, followed by gel-filtration chromatography. The formation of small
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 crystals of hRARγ LBD in complex with T-RA in the preliminary crystallization trials 
shows promising crystallization possibilities.  Further efforts will focus on improving the 
quality of single crystals co-crystallized by the complex of hRARγ LBD and T-RA or 
heteroarotinoids.  
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APPENDICES 
 
I. DNA Sequencing Results for Recombinant hRARγ LBD 
 
hRARγ LBD/T7 promoter primer: 
TGTAGTGGCGTACATTCCCCTCTGAATAATTTTGTTTAACTTTAAGAAGGAGA
TATACATATGCGGGGTTCTCATCATCATCATCATCATGGTATGGCTAGCATGA
CTGGTGGACAGCAAATGGGTCGGGATCTGTACGACGATGACGATAAGGATCA
TCCCTTCACCGACAGCTATGAGCTGAGCCCTCAGTTAGAAGAGCTCATCA
CCAAGGTCAGCAAAGCCCATCAGGAGACTTTCCCCTCGCTCTGCCAGCT
GGGCAAGTATACCACGAACTCCAGTGCAGACCACCGCGTGCAGCTGGAT
CTGGGGCTGTGGGACAAGTTCAGTGAGCTGGCTACCAAGTGCATCATCA
AGATCGTGGAGTTTGCCAAGCGGTTGCCTGGCTTTACAGGGCTCAGCAT
TGCTGACCAGATCACTCTGCTCAAAGCTGCCTGCCTAGATATCCTGATGC
TGCTATCTGCACAAGGTACACCCCAGAGCAgGACACCATGACCTTCTCCG
ACGGGCTGACCCTGAACCGGACCCAGATGCACAATGCCGGCTTCGGGCC
CCTCACAGACCTTGTCTTTGCCTTTGCTGGGCAGCTCCTGCCCCTGGAG
ATGGATGACACCGAGACAGGGCTGCTCAGCGCCATCTGCCTCATCTGCG
GAGACCGCATGGACCTGGAGGAGCCCGAAAAAGTGGACAAGCTGCAGG
AGCCACTGCTGGAAGCCCTGAGGCTGTACGCCCGGCGCCGGCGGCCCA
GCCAGCCCTACATGTTCCCAAGGATGCTAATGAAAATCACCGACCTCCG
GGGCATCAGCACTAAGGGAGCTGAAAGGGCCATTACTCTGAAGATGGAG
ATTCCAGGCCCGATGCCTCCCTTAATCCGAGAGATGCTGGAGAACCCTG
AAATGTTTGAGAAGGGCGAGCTCAACGATCCGGCTGCTAACAAAGCCCGAA
AGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATACCCTTG
GGGCCTCTAAACGGGTCTTGAGGAGTTTTTGCTGAAAGGAGGAACTATATCC
GGATATCCCGCAGAGCCCGCAGTACCGGCATAACCCAAGCCCTATGCTACAG
CATCAGGGTGACGTGCCGAGGATGACGATGAGCGCATGTAGATTTCATACAC
GGTGCTGACTGGCGTAGCATTTACTGGGATAACTACGCATAAGCCTATCGAG
GATAGCGTCAAACTGGAATAGTCCTGAAGAAGAAAGCCTCGGTGTATAGCGC 
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hRARγ LBD/T7 terminator primer: 
GGTCAACACAATCGCTTCTTTCGGCTTTGTTAGCAGCCGGACGTTGACCTCGC
CCTTCTCAAACATTTCAGGGTTCTCCAGCATCTCTCGGATTAAGGGAGGC
ATCGGGCCTGGAATCTCCATCTTCAGAGTAATGGCCCTTTCAGCTCCCTT
AGTGCTGATGCCCCGGAGGTCGGTGATTTTCATTAGCATCCTTGGGAAC
ATGTAGGGCTGGCTGGGCCGCCGGCGCCGGGCGTACAGCCTCAGGGCT
TCCAGCAGTGGCTCCTGCAGCTTGTCCACTTTTTCGGGCTCCTCCAGGTC
CATGCGGTCTCCGCAGATGAGGCAGATGGCGCTGAGCAGCCCTGTCTCG
GTGTCATCCATCTCCAGGGGCAGGAGCTGCCCAGCAAAGGCAAAGACAA
GGTCTGTGAGGGGCCCGAAGCCGGCATTGTGCATCTGGGTCCGGTTCAG
GGTCAGCCCGTCGGAGAAGGTCATGGTGTCcTGCTCTGGGGTGTACCTT
GTGCAGATACGCAGCATCAGGATATCTAGGCAGGCAGCTTTGAGCAGAG
TGATCTGGTCAGCAATGCTGAGCCCTGTAAAGCCAGGCAACCGCTTGGC
AAACTCCACGATCTTGATGATGCACTTGGTAGCCAGCTCACTGAACTTGT
CCCACAGCCCCAGATCCAGCTGCACGCGGTGGTCTGCACTGGAGTTCGT
GGTATACTTGCCCAGCTGGCAGAGCGAGGGGAAAGTCTCCTGATGGGCT
TTGCTGACCTTGGTGATGAGCTCTTCTAACTGAGGGCTCAGCTCATAGCT
GTCGGTGAAGGGATGATCCTTATCGTCATCGTCGTACAGATCCCGACCCATT
TGCTGTCCACCAGTCATGCTAGCCATACCATGATGATGATGATGATGAGAAC
CCCGCATATGTATATCTCCTTCTTAAAGTTAAACAAAATTATTTCTAGAGGGG
AATTGTTATCCGCTCACAATTCCCCTATAGTGAGTCGTATTAATTTCGCGGGA
TCGAGATCTCGATCCTCTACGCCGGACGCATCGTGGCCCGGCATCACCGGCG
CACAGGTGCGTTGCTGCGCTATTTCGCGACATCACGATGGGGAGATCGGGCT
CGCCACTTCGGGCTCATGAGCGCTTGTTCCGGCGTGGGTATGTTGCAGCTCAT
GACGGGGAACTGTGGCGCAATTCATGCATGCACATCTGCGCGCGGGCTTAA 
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Note: 
 
The bold sequence comes from the gene of hRARγ LBD, and the rest of sequence is from 
the plasmid pET100/D-TOPO. 
 
ATG: Start codon; 
CATCATCATCATCATCAT: 6xHis tag; 
GATCTGTACGACGATGACGATAAG: EK recognition site; 
CACC: Overhang addition to the primer 
CAg (in complementary sequence, it is “cTG”): The “A” was substituted by “g” in the 
cloned sequence. This is a silent mutation. Both “CAA” and “CAG” are translated into 
“Gln”. 
 
The chromatograms opened by software of FinchTV (Finch Trace Viewer, Geospiza) 
show the nucleotide sequence data of the construct hRARγ LBD/pET100/D- TOPO. Each 
of the trace peaks correspond to a base that is displayed on the top of the chromatograms. 
The peaks are generated in a fluorescence spectrum. Each of the base types is shown with 
different colors. The reliability of base identification is dependent on the peak height of 
the traces. The greater the peak height, the more reliable the base identification.   
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